On June 15, 2023, Mike HARKINS, Vice President of Global Sales at NanoString Technologies, Diane Lince, Vice President of Global Marketing, and Su Zhongmei, General Manager of China, visited the headquarters of Dunwill Medical to participate in the "Space Multiomics Technology and Applications Seminar" and awarded Dunwill Medical the Certificate and Medal of Excellence of GeoMx® Digital Spatial Profiler（DSP）Space Multiomics Platform. This certification signifies that Dunwill Medical has continuously provided customers with high-quality space omics services. As a DSP spatial omics service provider certified by the NanoString Center of Excellence, Dunwill Medical will continue to uphold its original mission of “powering the future of medicine” and make unremitting efforts to promote the development of cutting-edge research in spatial omics.

Firstly, Mr. Hou Ying, Executive Director of Market and Strategic Development Center of Shanghai Dunwill Medical, delivered an opening speech at the conference. He stated that Dunwill Medical has always been committed to becoming a leading global company in the research and commercialization of original biomarkers. He hopes to collaborate with clinical doctors in China to develop innovative translational medicine models with Dunwill characteristics, and ultimately achieve the vision of "powering the future of medicine". At the same time, the development of Dunwill cannot be separated from the help and support of important strategic partners such as NanoString. We look forward to continuous deepening of cooperation between the two companies and jointly exploring the infinite potential of space omics in the future.

Mr. Hou Ying, Executive Director of Market and Strategic Development Center, Shanghai Dunwill Medical

Over the course of 17 years of development, Dunwill Medical has been committed to becoming a leading global company in the research and commercialization of original biomarkers. By utilizing multiple omics techniques and working with clinical experts to study the development mechanisms of complex disease from the " spatial and temporal dimension," Dunwill Medical has developed original clinical IVD products with own independent intellectual property rights. The leading digital space multiomics analysis platform introduced by the company - NanoString GeoMx® DSP, combined with Illumina's high-throughput sequencing platform, provides a flexible and powerful spatial omics solution that can meet the needs of researchers from discovery to translational research. After the introduction of DSP platform, the company has carried out extensive research in liver cancer, diabetes, and other fields, and has made gratifying achievements. Therefore, the space multiomics platform is an indispensable and important part of Dunwill’s journey to achieve its mission and vision. At the same time, this year we have also completed the completion and relocation of the new headquarters building, and the brand-new factory laboratory has provided strong support for the accuracy and precision of experiments.

In the past 17 years, Dunwill has accumulated valuable experience in clinical cooperation and innovation transformation with top hospitals in China. On the path of medical innovation, we will always respect science, continuously develop more original research products under the "medicine-research-production" ecosystem, serve Chinese patients and doctors, and look forward to creating an innovative transformation medicine model with Dunwill's characteristics, and fulfil our mission. At the same time, Dunwill also needs important strategic partners like NanoString, and looking forward to continuous deepening of cooperation between the two companies to jointly explore the infinite potential of space omics in the future.

Subsequently, Mr. Mike Harkins, Vice President of Global Sales, and Ms. Diane Lince, Vice President of Global Marketing of NanoString, also delivered welcoming speeches, expressing their great confidence and promising prospects for the long-term and deep cooperation between NanoString Technologies and Dunwill Medical to jointly promote the development and application of space biology in China.

Mr. Harkins said, "Thanks Dunhui for choosing GeoMx® DSP platform, Nasostring has always adhered to the concept of customer first. We hope to help our customers gain more new biological insights and help our customers and partners achieve their success, while developing innovative technologies to change the way patients are treated and diseases are solved.

Mr. Mike Harkins, Vice President of Global Sales, NanoString

Ms. Diane Lince said, "Space omics is a current technological hotspot, and we empathize with Dunwill's mission. We will spare no effort in providing support and assistance, and look forward to achieving better results in future cooperation."

Ms. Diane Lince, Vice President of Global Marketing, NanoString

Afterwards, Hu Xianghua, Deputy Director of Marketing Research, Illumina, also delivered a welcome speech. He stated that Dunwill and NanoString are very important partners of Illumina and he is pleased to witness today's certification ceremony. In recent years, due to the deep cooperation between Illumina and Dunwill, a lot of work has been carried out in the fields of tumor targeted detection and ctDNA clinical drug validation. Due to the significant improvement in sequencing flux and data processing efficiency of the latest launched NovaSeq X Plus, it is more suitable for the significant increase in space omics sample size and data volume, providing strong technical energy for the development of more related research projects. I hope the cooperation with Dunhui and Nanostring will be deepened in the future, jointly build end-to-end solutions, further promote the transformation of scientific research results into clinical practice, accelerating the release of the potential of spatial omics and multi omics, and helping human health.

Hu Xianghua, Deputy Director of Marketing Research, Illumina

Researcher Li Huating from the Shanghai Diabetes Research Institute of the Sixth People's Hospital presented a wonderful academic report entitled "Application and Latest Progress of Space omics in the Research of Molecular Mechanisms of Obesity related Metabolic Diseases". Researcher Li Huating introduced space omics technology and development trends, as well as the application of spatial omics in the field of obesity related metabolic diseases. Researcher Li, in cooperation with Dunwill Medical, intends to use space multiomics as a powerful tool for mechanism research, and conduct in-depth exploration in the pathogenesis of type I diabetes, progress of nonalcoholic fatty liver disease, liver fibrosis and other fields. She believes that only through "dimension upgrading" thinking can we understand the essence of things, focus on key issues, and thus carry out "dimension reduction" strikes - finding the key ways to solve problems. Just like the study of space multiomics, it can help us understand the role of tissue cells in the spatial environment, understand the mechanisms of disease occurrence and development. We also hope that through this research, the results can be transformed into clinical prediction, diagnosis, or prevention in the future, so as to move forward and promote the health of the whole population.

Li Huating, Researcher, Shanghai Diabetes Research Institute of the Sixth People's Hospital

Niu Luyao, the Marketing Manager of NanoString China, and Tan Bo, space omics product expert, shared reports on "nCounter Fluorescent Barcode Multi Target Analysis Technology" and "NanoString Space Full Transcriptome and Single Cell Space In Situ Solutions", introducing NanoString's technology platform and solutions, as well as its technological deployment and latest research and development progress in the field of space biology.

Niu Luyao, Marketing Manager, NanoString

Tan Bo, Space omics Product Expert, NanoString

Subsequently, Jin Qihuang, Executive Director of Biomarker Research at Dunwill Medical, presented a keynote report titled "Discoveries of Space Multiomics Technologies and Biomarkers". Dr. Jin introduced space multi omics technology and applications, as well as project cases of biomarker research. Dunwill Medical has been committed to becoming a leading global company in the research and commercialization of original biomarkers. By utilizing multiple omics techniques and working with clinical experts to study the development mechanisms of complex disease from the " spatial and temporal dimension," Dunwill Medical has developed original clinical IVD products with own independent intellectual property rights. Since the GeoMx® DSP platform introduced in 2021, it has carried out extensive research in liver cancer, diabetes and other fields, and has made gratifying achievements. As a technology platform in the future, the most important task is to discover biomarkers through clinical samples, develop high-quality products, and create more possibilities for modern medicine.

Finally, Dunwill Medical and NanoString Technologies officially held the Center of Excellence certificate ceremony. This certification is not only a recognition of the phased achievements achieved through cooperation between both parties, but also a shared vision for future development. In the future, NanoString and Dunhui Medical will continue to deepen cooperation in cutting-edge space omics research, translational medicine applications and other fields, promote the development of precision medicine, and better serve clinical and scientific research with new technologies and achievements.